Milk of Cow and Goat, Immunized by Recombinant Protein Vaccine ZF-UZ-VAC2001(Zifivax), Contains Neutralizing Antibodies Against SARS-CoV-2 and Remains Active After Standard Milk Pasteurization.

Autor:	Garib V; Division of Immunopathology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Katsamaki S; Centre of Advanced Technology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Turdikulova S; Centre of Advanced Technology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Levitskaya Y; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan.; Centre of Advanced Technology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Zahidova N; Scientific and Diagnostical Centre of Laboratory Technology 'Defactum Laboratories', Tashkent, Uzbekistan., Bus G; Scientific and Diagnostical Centre of Laboratory Technology 'Defactum Laboratories', Tashkent, Uzbekistan., Karamova K; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Rakhmedova M; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Magbulova N; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Bruhov A; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Garib FY; International Centre of Molecular Allergology, Ministry of Innovative Development of the Republic of Uzbekistan, Tashkent, Uzbekistan., Abdurakhmonov IY; Centre of Genomics and Bioinformatics, Academy of Sciences of Uzbekistan, Tashkent, Uzbekistan.
Jazyk:	angličtina
Zdroj:	Frontiers in nutrition [Front Nutr] 2022 Jun 13; Vol. 9, pp. 901871. Date of Electronic Publication: 2022 Jun 13 (Print Publication: 2022).
DOI:	10.3389/fnut.2022.901871
Abstrakt:	Here, we present the first experimental validation of the possibility for obtaining immune milk with neutralizing antibodies against SARS-CoV-2 from vaccinated cows and goat using approved recombinant protein human coronavirus vaccine, ZF-UZ-VAC2001, in the Republic of Uzbekistan. In the period of 2 weeks after first vaccination, we detected the neutralizing antibodies against coronavirus in the blood serum of vaccinated animals. The neutralizing activity, in its peak on the 21st day after receiving the third dose (77th day from first dose), was effective in neutralization test using a live SARS-CoV-2 in Vero E6 cells, even after 120-fold serum titration. In cows receiving three dose of human vaccine, the MAGLUMI ® SARS-CoV-2 neutralizing antibody competitive chemiluminescence immunoassay revealed that colostrum of the first day after calving had a greater activity to neutralize the SARS-CoV-2 compared to colostrum of subsequent three days (4.080 μg/ml vs 2.106, 1.960 and 1.126 μg/ml). In comparison, the neutralizing activity for goat and cow milk was 1.486 μg/ml and 0.222 μg/ml, respectively. We observed a positive correlation of receptor-binding domain (RBD)-specific IgG antibodies between the serum of actively immunized cow and milk-feeding calf during the entire course of vaccination ( r = 0.95, p = 0.05). We showed an optimal regime for immune milk pasteurization at 62.5°C for 30 min, which retained specific neutralizing activity to SARS-CoV-2, potentially useful for passive immunization against coronavirus infection threats as an additive approach to the vaccination. This strategy, as a supportive approach to the vaccination, could also be applicable for directly reducing the effect of COVID-19 infection in gastrointestinal tract, supporting mucosal immunity. Competing Interests: The authors declare that the study concept and results are filed for patenting at the Intellectual Property Agency under the Ministry of Justice of the Republic of Uzbekistan with pending applications No. IAP 2021 0365 and IAP 2022 0054. The reviewer DM declared a shared affiliation with the author VG to the handling editor at the time of review. (Copyright © 2022 Garib, Katsamaki, Turdikulova, Levitskaya, Zahidova, Bus, Karamova, Rakhmedova, Magbulova, Bruhov, Garib and Abdurakhmonov.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu